Localized prostate cancer

New England Journal of Medicine

Volumn 357, Issue 26, 2007, Pages 2696-2705

  Walsh, Patrick C ^a   DeWeese, Theodore L ^b   Eisenberger, Mario A ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; DIGITAL RECTAL EXAMINATION; ECHOGRAPHY; GLEASON SCORE; HISTOLOGY; HUMAN; HUMAN TISSUE; LIFE EXPECTANCY; MALE; NEEDLE BIOPSY; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; SEXUAL FUNCTION; TREATMENT PLANNING; ADENOCARCINOMA; BLOOD; METHODOLOGY; PATHOLOGY; PRACTICE GUIDELINE; PROSTATE TUMOR; PROSTATECTOMY; REVIEW;

PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; AGED; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 37549020086     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp0706784     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90.
3. Walsh PC, Worthington JF. Dr. Patrick Walsh's guide to surviving prostate cancer. 2nd ed. New York: Warner Wellness, 2007.
4. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69:1095-101.
5. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-23.
6. Han M, Walsh PC, Catalona WJ, et al. Updated recurrence-free survival (RFS) prediction model following radical prostatectomy (RRP). J Urol 2007;177:Suppl:110. abstract.
7. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:715-7.
8. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol 2006;13:57-9.
9. Freedland SJ, Partin AW. Prostate-specific antigen: update 2006. Urology 2006;67:458-60.
10. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Free full text preoperative PSA velocity and the risk of death from prostate cancer after radial prostatectomy. N Engl J Med 2004;351:125-35.
11. Gretzer MB, Epstein JI, Pound CR, Walsh PC, Partin AW. Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence. Urology 2002;60:1034-9.
12. Augustin H, Eggert T, Wenske S, et al. Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer. J Urol 2004;171:177-81.
13. Greene KL, Meng MV, Elkin EP, et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from Cancer of the Prostate Strategic Urological Research Endeavor (CAPSURE). J Urol 2004;171:2255-9.
14. NCCN Clinical Practice Guidelines in Oncology: prostate cancer. V.2.2007. National Comprehensive Cancer Network, 2007. (Accessed November 30, 2007, at http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf.)
15. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84.
16. Epstein JI, Chan DW, Sokoll LJ, et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998;160:2407-11.
17. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
18. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:8165-9.
19. Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006;98:355-7.
20. Holmberg L, Bill-Axelson A, Garmo H, et al. Prognostic markers under watchful waiting and radical prostatectomy. Hematol Oncol Clin North Am 2006;20:845-55.
21. Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A. Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys 2007;67:1074-81.
22. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
23. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233-9.
24. Litwin MS, Gore JL, Kwan L, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 2007;109:2239-47.
25. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007;67:327-33.
26. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006;176:1415-9.
27. Brown MW, Brooks JP, Albert PS, Poggi MM. An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma. Prostate Cancer Prostatic Dis 2007;10:189-93.
28. Nelson B, Kaufman M, Broughton G, et al. Comparison of length of hospital stay between radical retropubic prostatectomy and robotic assisted laparoscopic prostatectomy. J Urol 2007;177:929-31.
29. Touijer K, Kuroiwa K, Saranchuk JW, et al. Quality improvement in laparoscopic radical prostatectomy for pT2 prostate cancer: impact of video documentation review on positive surgical margin. J Urol 2005;173:765-8.
30. Chuang A-Y, Nielsen ME, Hernandez DJ, Walsh PC, Epstein JI. The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy. J Urol 2007;178:1306-10.
31. Walsh PC. The discovery of the cavernous nerves and development of nerve-sparing radical prostatectomy. J Urol 2007;177:1632-5.
32. Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004;172:2227-31.
33. Saranchuk JW, Kattan MW, Elkin E, Touijer AK, Scardino PT, Eastham JA. Achieving optimal outcomes after radical prostatectomy. J Clin Oncol 2005;23:4146-51.
34. Penson DF, McLerran D, Feng Z, et al. 5-Year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes study. J Urol 2005;173:1701-5.
35. Thompson I, Thrasher JB, Gunnar A, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177:2106-31.
36. Vickers AJ, Bianco FJ, Serio AM, et al. The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst 2007;99:1171-7.
37. Porter CR, Kodama K, Gibbons RP, et al. 25-Year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol 2006;176:569-74.
38. Roach M III, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-74.
39. Andriole GL, Levin DL, Crawford ED, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005;97:433-8.
40. Postma R, Schroder FH, van Leenders GJ, et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - Section Rotterdam: a comparison of two rounds of screening. Eur Urol 2007;52:89-97.
41. Mills N, Metcalfe C, Ronsmans C, et al. A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study). Contemp Clin Trials 2006;27:413-9.
42. Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 1994;152:1910-4.
43. Aus G. Current status of HIFU and cryotherapy in prostate cancer - a review. Eur Urol 2006;50:927-34.